Oct 01, 2020
Debiopharm Launches TrilynX - A Large-Scale Phase III Clinical Trial to Further Evaluate Xevinapant in the Treatment of Head & Neck Cancer
Sep 22, 2020
Debiopharm Honored as a 2020 Swiss Biotech Success Story Winner For Outstanding Achievements Over 40 Years
Sep 17, 2020
Debiopharm to Present Late Breaking Head & Neck Cancer Abstract at the 2020 European Society of Medical Oncology Congress
Jul 07, 2020
Nucleai Secured $6.5M Series-A Initial Closing Led by Debiopharm To Advance AI-Powered Precision Oncology Platform
Jun 10, 2020
Debiopharm's Novel Microbiome Remodeling Program Licensed to Takeda for the Treatment of Gastrointestinal Disorders
May 26, 2020
Acquisition of Debiopharm's Investment Portfolio Company Kaiku Health Broadens Patient Access to Digital Oncology Intervention
Feb 27, 2020
FDA Grants Breakthrough Therapy Designation for Debiopharm's Novel Chemo-Radio Sensitizer Debio 1143 for Front-line Treatment of Head & Neck Cancer
Jan 09, 2020
Novadiscovery Raises Series A Financing to Scale its in silico Clinical Trial Platform - Debiopharm Leads the Round With EUR 5 Million
Jan 08, 2020
Knight Partners With Debiopharm for the Commercialization of Trelstar® in Canada
Oct 09, 2019
A Pancreatic and Colorectal Cancer Trial Initiated to Address the Needs of Patients With Immune Checkpoint Inhibitor (ICI)-Resistant Disease by Combining Debiopharm's Debio 1143 IAP Antagonist With Keytruda®
Sep 09, 2019
BC Platforms Provides Complete Data Management Solution for Debiopharm's Oncology Development Portfolio
May 30, 2019
Caris Life Sciences Partners with Debiopharm International SA to Develop Companion Diagnostic for Detection of Rare FGFR Fusions Using Novel Molecular Intelligence (MI) Transcriptome(TM)
May 21, 2019
Debiopharm Expands its Immuno-Oncology Development Program for Debio 1143, with the First IAP Inhibitor/Nivolumab Combination Trial
May 14, 2019
Debiopharm Awarded $2.1 Million From CARB-X in the Fight Against a Highly Resistant Nosocomial-Pneumonia Causing Superbug
Apr 30, 2019
GenePOC, a Subsidiary of Debiopharm Group, Reaches an Agreement With Meridian Bioscience for the Acquisition of Their Molecular Diagnostics Business
Apr 01, 2019
Debiopharm Releases Results of 3 Key Oncology Compound Programs at the 2019 American Association for Cancer Research (AACR) Conference in Atlanta, GA
Feb 14, 2019
Debiopharm International SA Initiates FUZE, a Clinical Trial Phase II Study Evaluating Debio 1347 in Advanced Solid Tumors Harboring an FGFR fusion
Jan 07, 2019
Debiopharm Group Regains the Commercial Rights to Trelstar® (Triptorelin pamoate) and Looks for New Partners in North America
Oct 23, 2018
GenePOC® Launches its GenePOC® CDiff Test in Canada
Oct 11, 2018
Debiopharm International SA and the Paul Scherrer Institute Announce a Licensing Agreement for the Development of a Novel Targeted Radiotherapeutic Product in Oncology